Food & Beverages
Global Sialylated Human Milk Oligosaccharides (HMO) Market Outlook, In‑Depth Analysis & Forecast to 2031
- Nov 18, 25
- ID: 606928
- Pages: 137
- Figures: 139
- Views: 1
Report Includes:
This definitive report equips business leaders, decision-makers and stakeholders with a 360° view of the global Sialylated Human Milk Oligosaccharides (HMO) market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region's dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Chr. Hansen (Jennewein Biotechnologie GmgH)
DSM (Glycom A/S)
Inbiose
Kyowa Hakko Bio
GeneChem Inc.
FrieslandCampina Ingredients
Segment by Type
3'-Sialyllactose
6'-Sialyllactose
Segment by Application
Infant Formula
Food
Others
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Sialylated Human Milk Oligosaccharides (HMO) study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; top manufactures 2024 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips business leaders, decision-makers and stakeholders with a 360° view of the global Sialylated Human Milk Oligosaccharides (HMO) market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region's dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Chr. Hansen (Jennewein Biotechnologie GmgH)
DSM (Glycom A/S)
Inbiose
Kyowa Hakko Bio
GeneChem Inc.
FrieslandCampina Ingredients
Segment by Type
3'-Sialyllactose
6'-Sialyllactose
Segment by Application
Infant Formula
Food
Others
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Sialylated Human Milk Oligosaccharides (HMO) study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; top manufactures 2024 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Sialylated Human Milk Oligosaccharides (HMO): Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Sialylated Human Milk Oligosaccharides (HMO) Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 3'-Sialyllactose
1.2.3 6'-Sialyllactose
1.3 Market Segmentation by Application
1.3.1 Global Sialylated Human Milk Oligosaccharides (HMO) Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Infant Formula
1.3.3 Food
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Sialylated Human Milk Oligosaccharides (HMO) Revenue Estimates and Forecasts 2020-2031
2.2 Global Sialylated Human Milk Oligosaccharides (HMO) Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Sialylated Human Milk Oligosaccharides (HMO) Sales Estimates and Forecasts 2020-2031
2.4 Global Sialylated Human Milk Oligosaccharides (HMO) Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Sialylated Human Milk Oligosaccharides (HMO) Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Sialylated Human Milk Oligosaccharides (HMO) Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 3'-Sialyllactose Market Size by Manufacturers
3.5.2 6'-Sialyllactose Market Size by Manufacturers
3.6 Global Sialylated Human Milk Oligosaccharides (HMO) Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Sialylated Human Milk Oligosaccharides (HMO) Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Sialylated Human Milk Oligosaccharides (HMO) Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Sialylated Human Milk Oligosaccharides (HMO) Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Sialylated Human Milk Oligosaccharides (HMO) Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Sialylated Human Milk Oligosaccharides (HMO) Sales and Revenue by Type (2020-2031)
6.4 North America Sialylated Human Milk Oligosaccharides (HMO) Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Sialylated Human Milk Oligosaccharides (HMO) Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Sialylated Human Milk Oligosaccharides (HMO) Sales and Revenue by Type (2020-2031)
7.4 Europe Sialylated Human Milk Oligosaccharides (HMO) Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Sialylated Human Milk Oligosaccharides (HMO) Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Sialylated Human Milk Oligosaccharides (HMO) Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Sialylated Human Milk Oligosaccharides (HMO) Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Sialylated Human Milk Oligosaccharides (HMO) Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Sialylated Human Milk Oligosaccharides (HMO) Sales and Revenue by Type (2020-2031)
9.4 Central and South America Sialylated Human Milk Oligosaccharides (HMO) Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Sialylated Human Milk Oligosaccharides (HMO) Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Sialylated Human Milk Oligosaccharides (HMO) Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Sialylated Human Milk Oligosaccharides (HMO) Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Sialylated Human Milk Oligosaccharides (HMO) Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Chr. Hansen (Jennewein Biotechnologie GmgH)
11.1.1 Chr. Hansen (Jennewein Biotechnologie GmgH) Corporation Information
11.1.2 Chr. Hansen (Jennewein Biotechnologie GmgH) Business Overview
11.1.3 Chr. Hansen (Jennewein Biotechnologie GmgH) Sialylated Human Milk Oligosaccharides (HMO) Product Models, Descriptions and Specifications
11.1.4 Chr. Hansen (Jennewein Biotechnologie GmgH) Sialylated Human Milk Oligosaccharides (HMO) Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Chr. Hansen (Jennewein Biotechnologie GmgH) Sialylated Human Milk Oligosaccharides (HMO) Sales by Product in 2024
11.1.6 Chr. Hansen (Jennewein Biotechnologie GmgH) Sialylated Human Milk Oligosaccharides (HMO) Sales by Application in 2024
11.1.7 Chr. Hansen (Jennewein Biotechnologie GmgH) Sialylated Human Milk Oligosaccharides (HMO) Sales by Geographic Area in 2024
11.1.8 Chr. Hansen (Jennewein Biotechnologie GmgH) Sialylated Human Milk Oligosaccharides (HMO) SWOT Analysis
11.1.9 Chr. Hansen (Jennewein Biotechnologie GmgH) Recent Developments
11.2 DSM (Glycom A/S)
11.2.1 DSM (Glycom A/S) Corporation Information
11.2.2 DSM (Glycom A/S) Business Overview
11.2.3 DSM (Glycom A/S) Sialylated Human Milk Oligosaccharides (HMO) Product Models, Descriptions and Specifications
11.2.4 DSM (Glycom A/S) Sialylated Human Milk Oligosaccharides (HMO) Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 DSM (Glycom A/S) Sialylated Human Milk Oligosaccharides (HMO) Sales by Product in 2024
11.2.6 DSM (Glycom A/S) Sialylated Human Milk Oligosaccharides (HMO) Sales by Application in 2024
11.2.7 DSM (Glycom A/S) Sialylated Human Milk Oligosaccharides (HMO) Sales by Geographic Area in 2024
11.2.8 DSM (Glycom A/S) Sialylated Human Milk Oligosaccharides (HMO) SWOT Analysis
11.2.9 DSM (Glycom A/S) Recent Developments
11.3 Inbiose
11.3.1 Inbiose Corporation Information
11.3.2 Inbiose Business Overview
11.3.3 Inbiose Sialylated Human Milk Oligosaccharides (HMO) Product Models, Descriptions and Specifications
11.3.4 Inbiose Sialylated Human Milk Oligosaccharides (HMO) Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Inbiose Sialylated Human Milk Oligosaccharides (HMO) Sales by Product in 2024
11.3.6 Inbiose Sialylated Human Milk Oligosaccharides (HMO) Sales by Application in 2024
11.3.7 Inbiose Sialylated Human Milk Oligosaccharides (HMO) Sales by Geographic Area in 2024
11.3.8 Inbiose Sialylated Human Milk Oligosaccharides (HMO) SWOT Analysis
11.3.9 Inbiose Recent Developments
11.4 Kyowa Hakko Bio
11.4.1 Kyowa Hakko Bio Corporation Information
11.4.2 Kyowa Hakko Bio Business Overview
11.4.3 Kyowa Hakko Bio Sialylated Human Milk Oligosaccharides (HMO) Product Models, Descriptions and Specifications
11.4.4 Kyowa Hakko Bio Sialylated Human Milk Oligosaccharides (HMO) Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Kyowa Hakko Bio Sialylated Human Milk Oligosaccharides (HMO) Sales by Product in 2024
11.4.6 Kyowa Hakko Bio Sialylated Human Milk Oligosaccharides (HMO) Sales by Application in 2024
11.4.7 Kyowa Hakko Bio Sialylated Human Milk Oligosaccharides (HMO) Sales by Geographic Area in 2024
11.4.8 Kyowa Hakko Bio Sialylated Human Milk Oligosaccharides (HMO) SWOT Analysis
11.4.9 Kyowa Hakko Bio Recent Developments
11.5 GeneChem Inc.
11.5.1 GeneChem Inc. Corporation Information
11.5.2 GeneChem Inc. Business Overview
11.5.3 GeneChem Inc. Sialylated Human Milk Oligosaccharides (HMO) Product Models, Descriptions and Specifications
11.5.4 GeneChem Inc. Sialylated Human Milk Oligosaccharides (HMO) Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 GeneChem Inc. Sialylated Human Milk Oligosaccharides (HMO) Sales by Product in 2024
11.5.6 GeneChem Inc. Sialylated Human Milk Oligosaccharides (HMO) Sales by Application in 2024
11.5.7 GeneChem Inc. Sialylated Human Milk Oligosaccharides (HMO) Sales by Geographic Area in 2024
11.5.8 GeneChem Inc. Sialylated Human Milk Oligosaccharides (HMO) SWOT Analysis
11.5.9 GeneChem Inc. Recent Developments
11.6 FrieslandCampina Ingredients
11.6.1 FrieslandCampina Ingredients Corporation Information
11.6.2 FrieslandCampina Ingredients Business Overview
11.6.3 FrieslandCampina Ingredients Sialylated Human Milk Oligosaccharides (HMO) Product Models, Descriptions and Specifications
11.6.4 FrieslandCampina Ingredients Sialylated Human Milk Oligosaccharides (HMO) Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 FrieslandCampina Ingredients Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Sialylated Human Milk Oligosaccharides (HMO) Industry Chain
12.2 Sialylated Human Milk Oligosaccharides (HMO) Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Sialylated Human Milk Oligosaccharides (HMO) Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Sialylated Human Milk Oligosaccharides (HMO) Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Sialylated Human Milk Oligosaccharides (HMO) Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Sialylated Human Milk Oligosaccharides (HMO) Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
1.1 Introduction to Sialylated Human Milk Oligosaccharides (HMO): Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Sialylated Human Milk Oligosaccharides (HMO) Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 3'-Sialyllactose
1.2.3 6'-Sialyllactose
1.3 Market Segmentation by Application
1.3.1 Global Sialylated Human Milk Oligosaccharides (HMO) Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Infant Formula
1.3.3 Food
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Sialylated Human Milk Oligosaccharides (HMO) Revenue Estimates and Forecasts 2020-2031
2.2 Global Sialylated Human Milk Oligosaccharides (HMO) Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Sialylated Human Milk Oligosaccharides (HMO) Sales Estimates and Forecasts 2020-2031
2.4 Global Sialylated Human Milk Oligosaccharides (HMO) Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Sialylated Human Milk Oligosaccharides (HMO) Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Sialylated Human Milk Oligosaccharides (HMO) Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 3'-Sialyllactose Market Size by Manufacturers
3.5.2 6'-Sialyllactose Market Size by Manufacturers
3.6 Global Sialylated Human Milk Oligosaccharides (HMO) Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Sialylated Human Milk Oligosaccharides (HMO) Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Sialylated Human Milk Oligosaccharides (HMO) Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Sialylated Human Milk Oligosaccharides (HMO) Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Sialylated Human Milk Oligosaccharides (HMO) Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Sialylated Human Milk Oligosaccharides (HMO) Sales and Revenue by Type (2020-2031)
6.4 North America Sialylated Human Milk Oligosaccharides (HMO) Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Sialylated Human Milk Oligosaccharides (HMO) Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Sialylated Human Milk Oligosaccharides (HMO) Sales and Revenue by Type (2020-2031)
7.4 Europe Sialylated Human Milk Oligosaccharides (HMO) Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Sialylated Human Milk Oligosaccharides (HMO) Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Sialylated Human Milk Oligosaccharides (HMO) Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Sialylated Human Milk Oligosaccharides (HMO) Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Sialylated Human Milk Oligosaccharides (HMO) Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Sialylated Human Milk Oligosaccharides (HMO) Sales and Revenue by Type (2020-2031)
9.4 Central and South America Sialylated Human Milk Oligosaccharides (HMO) Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Sialylated Human Milk Oligosaccharides (HMO) Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Sialylated Human Milk Oligosaccharides (HMO) Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Sialylated Human Milk Oligosaccharides (HMO) Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Sialylated Human Milk Oligosaccharides (HMO) Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Chr. Hansen (Jennewein Biotechnologie GmgH)
11.1.1 Chr. Hansen (Jennewein Biotechnologie GmgH) Corporation Information
11.1.2 Chr. Hansen (Jennewein Biotechnologie GmgH) Business Overview
11.1.3 Chr. Hansen (Jennewein Biotechnologie GmgH) Sialylated Human Milk Oligosaccharides (HMO) Product Models, Descriptions and Specifications
11.1.4 Chr. Hansen (Jennewein Biotechnologie GmgH) Sialylated Human Milk Oligosaccharides (HMO) Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Chr. Hansen (Jennewein Biotechnologie GmgH) Sialylated Human Milk Oligosaccharides (HMO) Sales by Product in 2024
11.1.6 Chr. Hansen (Jennewein Biotechnologie GmgH) Sialylated Human Milk Oligosaccharides (HMO) Sales by Application in 2024
11.1.7 Chr. Hansen (Jennewein Biotechnologie GmgH) Sialylated Human Milk Oligosaccharides (HMO) Sales by Geographic Area in 2024
11.1.8 Chr. Hansen (Jennewein Biotechnologie GmgH) Sialylated Human Milk Oligosaccharides (HMO) SWOT Analysis
11.1.9 Chr. Hansen (Jennewein Biotechnologie GmgH) Recent Developments
11.2 DSM (Glycom A/S)
11.2.1 DSM (Glycom A/S) Corporation Information
11.2.2 DSM (Glycom A/S) Business Overview
11.2.3 DSM (Glycom A/S) Sialylated Human Milk Oligosaccharides (HMO) Product Models, Descriptions and Specifications
11.2.4 DSM (Glycom A/S) Sialylated Human Milk Oligosaccharides (HMO) Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 DSM (Glycom A/S) Sialylated Human Milk Oligosaccharides (HMO) Sales by Product in 2024
11.2.6 DSM (Glycom A/S) Sialylated Human Milk Oligosaccharides (HMO) Sales by Application in 2024
11.2.7 DSM (Glycom A/S) Sialylated Human Milk Oligosaccharides (HMO) Sales by Geographic Area in 2024
11.2.8 DSM (Glycom A/S) Sialylated Human Milk Oligosaccharides (HMO) SWOT Analysis
11.2.9 DSM (Glycom A/S) Recent Developments
11.3 Inbiose
11.3.1 Inbiose Corporation Information
11.3.2 Inbiose Business Overview
11.3.3 Inbiose Sialylated Human Milk Oligosaccharides (HMO) Product Models, Descriptions and Specifications
11.3.4 Inbiose Sialylated Human Milk Oligosaccharides (HMO) Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Inbiose Sialylated Human Milk Oligosaccharides (HMO) Sales by Product in 2024
11.3.6 Inbiose Sialylated Human Milk Oligosaccharides (HMO) Sales by Application in 2024
11.3.7 Inbiose Sialylated Human Milk Oligosaccharides (HMO) Sales by Geographic Area in 2024
11.3.8 Inbiose Sialylated Human Milk Oligosaccharides (HMO) SWOT Analysis
11.3.9 Inbiose Recent Developments
11.4 Kyowa Hakko Bio
11.4.1 Kyowa Hakko Bio Corporation Information
11.4.2 Kyowa Hakko Bio Business Overview
11.4.3 Kyowa Hakko Bio Sialylated Human Milk Oligosaccharides (HMO) Product Models, Descriptions and Specifications
11.4.4 Kyowa Hakko Bio Sialylated Human Milk Oligosaccharides (HMO) Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Kyowa Hakko Bio Sialylated Human Milk Oligosaccharides (HMO) Sales by Product in 2024
11.4.6 Kyowa Hakko Bio Sialylated Human Milk Oligosaccharides (HMO) Sales by Application in 2024
11.4.7 Kyowa Hakko Bio Sialylated Human Milk Oligosaccharides (HMO) Sales by Geographic Area in 2024
11.4.8 Kyowa Hakko Bio Sialylated Human Milk Oligosaccharides (HMO) SWOT Analysis
11.4.9 Kyowa Hakko Bio Recent Developments
11.5 GeneChem Inc.
11.5.1 GeneChem Inc. Corporation Information
11.5.2 GeneChem Inc. Business Overview
11.5.3 GeneChem Inc. Sialylated Human Milk Oligosaccharides (HMO) Product Models, Descriptions and Specifications
11.5.4 GeneChem Inc. Sialylated Human Milk Oligosaccharides (HMO) Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 GeneChem Inc. Sialylated Human Milk Oligosaccharides (HMO) Sales by Product in 2024
11.5.6 GeneChem Inc. Sialylated Human Milk Oligosaccharides (HMO) Sales by Application in 2024
11.5.7 GeneChem Inc. Sialylated Human Milk Oligosaccharides (HMO) Sales by Geographic Area in 2024
11.5.8 GeneChem Inc. Sialylated Human Milk Oligosaccharides (HMO) SWOT Analysis
11.5.9 GeneChem Inc. Recent Developments
11.6 FrieslandCampina Ingredients
11.6.1 FrieslandCampina Ingredients Corporation Information
11.6.2 FrieslandCampina Ingredients Business Overview
11.6.3 FrieslandCampina Ingredients Sialylated Human Milk Oligosaccharides (HMO) Product Models, Descriptions and Specifications
11.6.4 FrieslandCampina Ingredients Sialylated Human Milk Oligosaccharides (HMO) Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 FrieslandCampina Ingredients Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Sialylated Human Milk Oligosaccharides (HMO) Industry Chain
12.2 Sialylated Human Milk Oligosaccharides (HMO) Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Sialylated Human Milk Oligosaccharides (HMO) Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Sialylated Human Milk Oligosaccharides (HMO) Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Sialylated Human Milk Oligosaccharides (HMO) Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Sialylated Human Milk Oligosaccharides (HMO) Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Sialylated Human Milk Oligosaccharides (HMO) Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Sialylated Human Milk Oligosaccharides (HMO) Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Sialylated Human Milk Oligosaccharides (HMO) Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Sialylated Human Milk Oligosaccharides (HMO) Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Sialylated Human Milk Oligosaccharides (HMO) Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Sialylated Human Milk Oligosaccharides (HMO) Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (Tons)
Table 7. Global Sialylated Human Milk Oligosaccharides (HMO) Sales by Region (2020-2025) & (Tons)
Table 8. Global Sialylated Human Milk Oligosaccharides (HMO) Sales by Region (2026-2031) & (Tons)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Sialylated Human Milk Oligosaccharides (HMO) Sales by Manufacturers (2020-2025) & (Tons)
Table 11. Global Sialylated Human Milk Oligosaccharides (HMO) Sales Share by Manufacturers (2020-2025)
Table 12. Global Sialylated Human Milk Oligosaccharides (HMO) Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Sialylated Human Milk Oligosaccharides (HMO) Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Sialylated Human Milk Oligosaccharides (HMO) by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Sialylated Human Milk Oligosaccharides (HMO) as of 2024)
Table 16. Global Sialylated Human Milk Oligosaccharides (HMO) Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Sialylated Human Milk Oligosaccharides (HMO) Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Kg)
Table 18. Key Manufacturers Sialylated Human Milk Oligosaccharides (HMO) Manufacturing Base and Headquarters
Table 19. Global Sialylated Human Milk Oligosaccharides (HMO) Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Sialylated Human Milk Oligosaccharides (HMO) Sales by Type (2020-2025) & (Tons)
Table 23. Global Sialylated Human Milk Oligosaccharides (HMO) Sales by Type (2026-2031) & (Tons)
Table 24. Global Sialylated Human Milk Oligosaccharides (HMO) Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Sialylated Human Milk Oligosaccharides (HMO) Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Sialylated Human Milk Oligosaccharides (HMO) ASP by Type (2020-2031) & (US$/Kg)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Sialylated Human Milk Oligosaccharides (HMO) Sales by Application (2020-2025) & (Tons)
Table 29. Global Sialylated Human Milk Oligosaccharides (HMO) Sales by Application (2026-2031) & (Tons)
Table 30. Sialylated Human Milk Oligosaccharides (HMO) High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Sialylated Human Milk Oligosaccharides (HMO) Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Sialylated Human Milk Oligosaccharides (HMO) Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Sialylated Human Milk Oligosaccharides (HMO) ASP by Application (2020-2031) & (US$/Kg)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Sialylated Human Milk Oligosaccharides (HMO) Growth Accelerators and Market Barriers
Table 37. North America Sialylated Human Milk Oligosaccharides (HMO) Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Sialylated Human Milk Oligosaccharides (HMO) Sales (Tons) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Sialylated Human Milk Oligosaccharides (HMO) Growth Accelerators and Market Barriers
Table 40. Europe Sialylated Human Milk Oligosaccharides (HMO) Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Sialylated Human Milk Oligosaccharides (HMO) Sales (Tons) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Sialylated Human Milk Oligosaccharides (HMO) Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Sialylated Human Milk Oligosaccharides (HMO) Sales (Tons) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Sialylated Human Milk Oligosaccharides (HMO) Growth Accelerators and Market Barriers
Table 45. Southeast Asia Sialylated Human Milk Oligosaccharides (HMO) Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Sialylated Human Milk Oligosaccharides (HMO) Investment Opportunities and Key Challenges
Table 47. Central and South America Sialylated Human Milk Oligosaccharides (HMO) Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Sialylated Human Milk Oligosaccharides (HMO) Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Sialylated Human Milk Oligosaccharides (HMO) Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Chr. Hansen (Jennewein Biotechnologie GmgH) Corporation Information
Table 51. Chr. Hansen (Jennewein Biotechnologie GmgH) Description and Major Businesses
Table 52. Chr. Hansen (Jennewein Biotechnologie GmgH) Product Models, Descriptions and Specifications
Table 53. Chr. Hansen (Jennewein Biotechnologie GmgH) Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 54. Chr. Hansen (Jennewein Biotechnologie GmgH) Sales Value Proportion by Product in 2024
Table 55. Chr. Hansen (Jennewein Biotechnologie GmgH) Sales Value Proportion by Application in 2024
Table 56. Chr. Hansen (Jennewein Biotechnologie GmgH) Sales Value Proportion by Geographic Area in 2024
Table 57. Chr. Hansen (Jennewein Biotechnologie GmgH) Sialylated Human Milk Oligosaccharides (HMO) SWOT Analysis
Table 58. Chr. Hansen (Jennewein Biotechnologie GmgH) Recent Developments
Table 59. DSM (Glycom A/S) Corporation Information
Table 60. DSM (Glycom A/S) Description and Major Businesses
Table 61. DSM (Glycom A/S) Product Models, Descriptions and Specifications
Table 62. DSM (Glycom A/S) Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 63. DSM (Glycom A/S) Sales Value Proportion by Product in 2024
Table 64. DSM (Glycom A/S) Sales Value Proportion by Application in 2024
Table 65. DSM (Glycom A/S) Sales Value Proportion by Geographic Area in 2024
Table 66. DSM (Glycom A/S) Sialylated Human Milk Oligosaccharides (HMO) SWOT Analysis
Table 67. DSM (Glycom A/S) Recent Developments
Table 68. Inbiose Corporation Information
Table 69. Inbiose Description and Major Businesses
Table 70. Inbiose Product Models, Descriptions and Specifications
Table 71. Inbiose Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 72. Inbiose Sales Value Proportion by Product in 2024
Table 73. Inbiose Sales Value Proportion by Application in 2024
Table 74. Inbiose Sales Value Proportion by Geographic Area in 2024
Table 75. Inbiose Sialylated Human Milk Oligosaccharides (HMO) SWOT Analysis
Table 76. Inbiose Recent Developments
Table 77. Kyowa Hakko Bio Corporation Information
Table 78. Kyowa Hakko Bio Description and Major Businesses
Table 79. Kyowa Hakko Bio Product Models, Descriptions and Specifications
Table 80. Kyowa Hakko Bio Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 81. Kyowa Hakko Bio Sales Value Proportion by Product in 2024
Table 82. Kyowa Hakko Bio Sales Value Proportion by Application in 2024
Table 83. Kyowa Hakko Bio Sales Value Proportion by Geographic Area in 2024
Table 84. Kyowa Hakko Bio Sialylated Human Milk Oligosaccharides (HMO) SWOT Analysis
Table 85. Kyowa Hakko Bio Recent Developments
Table 86. GeneChem Inc. Corporation Information
Table 87. GeneChem Inc. Description and Major Businesses
Table 88. GeneChem Inc. Product Models, Descriptions and Specifications
Table 89. GeneChem Inc. Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 90. GeneChem Inc. Sales Value Proportion by Product in 2024
Table 91. GeneChem Inc. Sales Value Proportion by Application in 2024
Table 92. GeneChem Inc. Sales Value Proportion by Geographic Area in 2024
Table 93. GeneChem Inc. Sialylated Human Milk Oligosaccharides (HMO) SWOT Analysis
Table 94. GeneChem Inc. Recent Developments
Table 95. FrieslandCampina Ingredients Corporation Information
Table 96. FrieslandCampina Ingredients Description and Major Businesses
Table 97. FrieslandCampina Ingredients Product Models, Descriptions and Specifications
Table 98. FrieslandCampina Ingredients Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 99. FrieslandCampina Ingredients Recent Developments
Table 100. Key Raw Materials Distribution
Table 101. Raw Materials Key Suppliers
Table 102. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 103. Milestones in Production Technology Evolution
Table 104. Distributors List
Table 105. Market Trends and Market Evolution
Table 106. Market Drivers and Opportunities
Table 107. Market Challenges, Risks, and Restraints
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
List of Figures
Figure 1. Sialylated Human Milk Oligosaccharides (HMO) Product Picture
Figure 2. Global Sialylated Human Milk Oligosaccharides (HMO) Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. 3'-Sialyllactose Product Picture
Figure 4. 6'-Sialyllactose Product Picture
Figure 5. Global Sialylated Human Milk Oligosaccharides (HMO) Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Infant Formula
Figure 7. Food
Figure 8. Others
Figure 9. Sialylated Human Milk Oligosaccharides (HMO) Report Years Considered
Figure 10. Global Sialylated Human Milk Oligosaccharides (HMO) Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2031) & (US$ Million)
Figure 12. Global Sialylated Human Milk Oligosaccharides (HMO) Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 13. Global Sialylated Human Milk Oligosaccharides (HMO) Revenue Market Share by Region (2020-2031)
Figure 14. Global Sialylated Human Milk Oligosaccharides (HMO) Sales (2020-2031) & (Tons)
Figure 15. Global Sialylated Human Milk Oligosaccharides (HMO) Sales (CAGR) by Region (2020-2031) (Tons)
Figure 16. Global Sialylated Human Milk Oligosaccharides (HMO) Sales Market Share by Region (2020-2031)
Figure 17. Top 5 and Top 10 Manufacturers Sialylated Human Milk Oligosaccharides (HMO) Sales Volume Market Share in 2024
Figure 18. Global Sialylated Human Milk Oligosaccharides (HMO) Revenue Market Share Ranking (2024)
Figure 19. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 20. 3'-Sialyllactose Revenue Market Share by Manufacturer in 2024
Figure 21. 6'-Sialyllactose Revenue Market Share by Manufacturer in 2024
Figure 22. Global Sialylated Human Milk Oligosaccharides (HMO) Sales Market Share by Type (2020-2031)
Figure 23. Global Sialylated Human Milk Oligosaccharides (HMO) Revenue Market Share by Type (2020-2031)
Figure 24. Global Sialylated Human Milk Oligosaccharides (HMO) Sales Market Share by Application (2020-2031)
Figure 25. Global Sialylated Human Milk Oligosaccharides (HMO) Revenue Market Share by Application (2020-2031)
Figure 26. North America Sialylated Human Milk Oligosaccharides (HMO) Sales YoY (2020-2031) & (Tons)
Figure 27. North America Sialylated Human Milk Oligosaccharides (HMO) Revenue YoY (2020-2031) & (US$ Million)
Figure 28. North America Top 5 Manufacturers Sialylated Human Milk Oligosaccharides (HMO) Sales Revenue (US$ Million) in 2024
Figure 29. North America Sialylated Human Milk Oligosaccharides (HMO) Sales Volume (Tons) by Type (2020- 2031)
Figure 30. North America Sialylated Human Milk Oligosaccharides (HMO) Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 31. North America Sialylated Human Milk Oligosaccharides (HMO) Sales Volume (Tons) by Application (2020-2031)
Figure 32. North America Sialylated Human Milk Oligosaccharides (HMO) Sales Revenue (US$ Million) by Application (2020-2031)
Figure 33. US Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2031) & (US$ Million)
Figure 34. Canada Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2031) & (US$ Million)
Figure 35. Mexico Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2031) & (US$ Million)
Figure 36. Europe Sialylated Human Milk Oligosaccharides (HMO) Sales YoY (2020-2031) & (Tons)
Figure 37. Europe Sialylated Human Milk Oligosaccharides (HMO) Revenue YoY (2020-2031) & (US$ Million)
Figure 38. Europe Top 5 Manufacturers Sialylated Human Milk Oligosaccharides (HMO) Sales Revenue (US$ Million) in 2024
Figure 39. Europe Sialylated Human Milk Oligosaccharides (HMO) Sales Volume (Tons) by Type (2020-2031)
Figure 40. Europe Sialylated Human Milk Oligosaccharides (HMO) Sales Revenue (US$ Million) by Type (2020-2031)
Figure 41. Europe Sialylated Human Milk Oligosaccharides (HMO) Sales Volume (Tons) by Application (2020-2031)
Figure 42. Europe Sialylated Human Milk Oligosaccharides (HMO) Sales Revenue (US$ Million) by Application (2020-2031)
Figure 43. Germany Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2031) & (US$ Million)
Figure 44. France Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2031) & (US$ Million)
Figure 45. U.K. Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2031) & (US$ Million)
Figure 46. Italy Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2031) & (US$ Million)
Figure 47. Russia Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2031) & (US$ Million)
Figure 48. Asia-Pacific Sialylated Human Milk Oligosaccharides (HMO) Sales YoY (2020-2031) & (Tons)
Figure 49. Asia-Pacific Sialylated Human Milk Oligosaccharides (HMO) Revenue YoY (2020-2031) & (US$ Million)
Figure 50. Asia-Pacific Top 8 Manufacturers Sialylated Human Milk Oligosaccharides (HMO) Sales Revenue (US$ Million) in 2024
Figure 51. Asia-Pacific Sialylated Human Milk Oligosaccharides (HMO) Sales Volume (Tons) by Type (2020- 2031)
Figure 52. Asia-Pacific Sialylated Human Milk Oligosaccharides (HMO) Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 53. Asia-Pacific Sialylated Human Milk Oligosaccharides (HMO) Sales Volume (Tons) by Application (2020-2031)
Figure 54. Asia-Pacific Sialylated Human Milk Oligosaccharides (HMO) Sales Revenue (US$ Million) by Application (2020-2031)
Figure 55. Indonesia Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2031) & (US$ Million)
Figure 56. Japan Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2031) & (US$ Million)
Figure 57. South Korea Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2031) & (US$ Million)
Figure 58. China Taiwan Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2031) & (US$ Million)
Figure 59. India Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2031) & (US$ Million)
Figure 60. Central and South America Sialylated Human Milk Oligosaccharides (HMO) Sales YoY (2020-2031) & (Tons)
Figure 61. Central and South America Sialylated Human Milk Oligosaccharides (HMO) Revenue YoY (2020-2031) & (US$ Million)
Figure 62. Central and South America Top 5 Manufacturers Sialylated Human Milk Oligosaccharides (HMO) Sales Revenue (US$ Million) in 2024
Figure 63. Central and South America Sialylated Human Milk Oligosaccharides (HMO) Sales Volume (Tons) by Type (2021-2031)
Figure 64. Central and South America Sialylated Human Milk Oligosaccharides (HMO) Sales Revenue (US$ Million) by Type (2020-2031)
Figure 65. Central and South America Sialylated Human Milk Oligosaccharides (HMO) Sales Volume (Tons) by Application (2020-2031)
Figure 66. Central and South America Sialylated Human Milk Oligosaccharides (HMO) Sales Revenue (US$ Million) by Application (2020-2031)
Figure 67. Brazil Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2025) & (US$ Million)
Figure 68. Argentina Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2025) & (US$ Million)
Figure 69. Middle East, and Africa Sialylated Human Milk Oligosaccharides (HMO) Sales YoY (2020-2031) & (Tons)
Figure 70. Middle East and Africa Sialylated Human Milk Oligosaccharides (HMO) Revenue YoY (2020-2031) & (US$ Million)
Figure 71. Middle East and Africa Top 5 Manufacturers Sialylated Human Milk Oligosaccharides (HMO) Sales Revenue (US$ Million) in 2024
Figure 72. Middle East and Africa Sialylated Human Milk Oligosaccharides (HMO) Sales Volume (Tons) by Type (2021-2031)
Figure 73. South America Sialylated Human Milk Oligosaccharides (HMO) Sales Revenue (US$ Million) by Type (2020-2031)
Figure 74. Middle East and Africa Sialylated Human Milk Oligosaccharides (HMO) Sales Volume (Tons) by Application (2020-2031)
Figure 75. Middle East and Africa Sialylated Human Milk Oligosaccharides (HMO) Sales Revenue (US$ Million) by Application (2020-2031)
Figure 76. GCC Countries Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2025) & (US$ Million)
Figure 77. Turkey Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2025) & (US$ Million)
Figure 78. Egypt Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2025) & (US$ Million)
Figure 79. South Africa Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2025) & (US$ Million)
Figure 80. Sialylated Human Milk Oligosaccharides (HMO) Industry Chain Mapping
Figure 81. Regional Sialylated Human Milk Oligosaccharides (HMO) Manufacturing Base Distribution (%)
Figure 82. Global Sialylated Human Milk Oligosaccharides (HMO) Production Market Share by Region (2020-2031)
Figure 83. Sialylated Human Milk Oligosaccharides (HMO) Production Process
Figure 84. Regional Sialylated Human Milk Oligosaccharides (HMO) Production Cost Structure
Figure 85. Channels of Distribution (Direct Vs Distribution)
Figure 86. Bottom-up and Top-down Approaches for This Report
Figure 87. Data Triangulation
Figure 88. Key Executives Interviewed
Table 1. Global Sialylated Human Milk Oligosaccharides (HMO) Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Sialylated Human Milk Oligosaccharides (HMO) Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Sialylated Human Milk Oligosaccharides (HMO) Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Sialylated Human Milk Oligosaccharides (HMO) Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Sialylated Human Milk Oligosaccharides (HMO) Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Sialylated Human Milk Oligosaccharides (HMO) Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (Tons)
Table 7. Global Sialylated Human Milk Oligosaccharides (HMO) Sales by Region (2020-2025) & (Tons)
Table 8. Global Sialylated Human Milk Oligosaccharides (HMO) Sales by Region (2026-2031) & (Tons)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Sialylated Human Milk Oligosaccharides (HMO) Sales by Manufacturers (2020-2025) & (Tons)
Table 11. Global Sialylated Human Milk Oligosaccharides (HMO) Sales Share by Manufacturers (2020-2025)
Table 12. Global Sialylated Human Milk Oligosaccharides (HMO) Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Sialylated Human Milk Oligosaccharides (HMO) Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Sialylated Human Milk Oligosaccharides (HMO) by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Sialylated Human Milk Oligosaccharides (HMO) as of 2024)
Table 16. Global Sialylated Human Milk Oligosaccharides (HMO) Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Sialylated Human Milk Oligosaccharides (HMO) Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Kg)
Table 18. Key Manufacturers Sialylated Human Milk Oligosaccharides (HMO) Manufacturing Base and Headquarters
Table 19. Global Sialylated Human Milk Oligosaccharides (HMO) Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Sialylated Human Milk Oligosaccharides (HMO) Sales by Type (2020-2025) & (Tons)
Table 23. Global Sialylated Human Milk Oligosaccharides (HMO) Sales by Type (2026-2031) & (Tons)
Table 24. Global Sialylated Human Milk Oligosaccharides (HMO) Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Sialylated Human Milk Oligosaccharides (HMO) Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Sialylated Human Milk Oligosaccharides (HMO) ASP by Type (2020-2031) & (US$/Kg)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Sialylated Human Milk Oligosaccharides (HMO) Sales by Application (2020-2025) & (Tons)
Table 29. Global Sialylated Human Milk Oligosaccharides (HMO) Sales by Application (2026-2031) & (Tons)
Table 30. Sialylated Human Milk Oligosaccharides (HMO) High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Sialylated Human Milk Oligosaccharides (HMO) Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Sialylated Human Milk Oligosaccharides (HMO) Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Sialylated Human Milk Oligosaccharides (HMO) ASP by Application (2020-2031) & (US$/Kg)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Sialylated Human Milk Oligosaccharides (HMO) Growth Accelerators and Market Barriers
Table 37. North America Sialylated Human Milk Oligosaccharides (HMO) Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Sialylated Human Milk Oligosaccharides (HMO) Sales (Tons) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Sialylated Human Milk Oligosaccharides (HMO) Growth Accelerators and Market Barriers
Table 40. Europe Sialylated Human Milk Oligosaccharides (HMO) Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Sialylated Human Milk Oligosaccharides (HMO) Sales (Tons) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Sialylated Human Milk Oligosaccharides (HMO) Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Sialylated Human Milk Oligosaccharides (HMO) Sales (Tons) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Sialylated Human Milk Oligosaccharides (HMO) Growth Accelerators and Market Barriers
Table 45. Southeast Asia Sialylated Human Milk Oligosaccharides (HMO) Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Sialylated Human Milk Oligosaccharides (HMO) Investment Opportunities and Key Challenges
Table 47. Central and South America Sialylated Human Milk Oligosaccharides (HMO) Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Sialylated Human Milk Oligosaccharides (HMO) Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Sialylated Human Milk Oligosaccharides (HMO) Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Chr. Hansen (Jennewein Biotechnologie GmgH) Corporation Information
Table 51. Chr. Hansen (Jennewein Biotechnologie GmgH) Description and Major Businesses
Table 52. Chr. Hansen (Jennewein Biotechnologie GmgH) Product Models, Descriptions and Specifications
Table 53. Chr. Hansen (Jennewein Biotechnologie GmgH) Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 54. Chr. Hansen (Jennewein Biotechnologie GmgH) Sales Value Proportion by Product in 2024
Table 55. Chr. Hansen (Jennewein Biotechnologie GmgH) Sales Value Proportion by Application in 2024
Table 56. Chr. Hansen (Jennewein Biotechnologie GmgH) Sales Value Proportion by Geographic Area in 2024
Table 57. Chr. Hansen (Jennewein Biotechnologie GmgH) Sialylated Human Milk Oligosaccharides (HMO) SWOT Analysis
Table 58. Chr. Hansen (Jennewein Biotechnologie GmgH) Recent Developments
Table 59. DSM (Glycom A/S) Corporation Information
Table 60. DSM (Glycom A/S) Description and Major Businesses
Table 61. DSM (Glycom A/S) Product Models, Descriptions and Specifications
Table 62. DSM (Glycom A/S) Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 63. DSM (Glycom A/S) Sales Value Proportion by Product in 2024
Table 64. DSM (Glycom A/S) Sales Value Proportion by Application in 2024
Table 65. DSM (Glycom A/S) Sales Value Proportion by Geographic Area in 2024
Table 66. DSM (Glycom A/S) Sialylated Human Milk Oligosaccharides (HMO) SWOT Analysis
Table 67. DSM (Glycom A/S) Recent Developments
Table 68. Inbiose Corporation Information
Table 69. Inbiose Description and Major Businesses
Table 70. Inbiose Product Models, Descriptions and Specifications
Table 71. Inbiose Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 72. Inbiose Sales Value Proportion by Product in 2024
Table 73. Inbiose Sales Value Proportion by Application in 2024
Table 74. Inbiose Sales Value Proportion by Geographic Area in 2024
Table 75. Inbiose Sialylated Human Milk Oligosaccharides (HMO) SWOT Analysis
Table 76. Inbiose Recent Developments
Table 77. Kyowa Hakko Bio Corporation Information
Table 78. Kyowa Hakko Bio Description and Major Businesses
Table 79. Kyowa Hakko Bio Product Models, Descriptions and Specifications
Table 80. Kyowa Hakko Bio Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 81. Kyowa Hakko Bio Sales Value Proportion by Product in 2024
Table 82. Kyowa Hakko Bio Sales Value Proportion by Application in 2024
Table 83. Kyowa Hakko Bio Sales Value Proportion by Geographic Area in 2024
Table 84. Kyowa Hakko Bio Sialylated Human Milk Oligosaccharides (HMO) SWOT Analysis
Table 85. Kyowa Hakko Bio Recent Developments
Table 86. GeneChem Inc. Corporation Information
Table 87. GeneChem Inc. Description and Major Businesses
Table 88. GeneChem Inc. Product Models, Descriptions and Specifications
Table 89. GeneChem Inc. Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 90. GeneChem Inc. Sales Value Proportion by Product in 2024
Table 91. GeneChem Inc. Sales Value Proportion by Application in 2024
Table 92. GeneChem Inc. Sales Value Proportion by Geographic Area in 2024
Table 93. GeneChem Inc. Sialylated Human Milk Oligosaccharides (HMO) SWOT Analysis
Table 94. GeneChem Inc. Recent Developments
Table 95. FrieslandCampina Ingredients Corporation Information
Table 96. FrieslandCampina Ingredients Description and Major Businesses
Table 97. FrieslandCampina Ingredients Product Models, Descriptions and Specifications
Table 98. FrieslandCampina Ingredients Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
Table 99. FrieslandCampina Ingredients Recent Developments
Table 100. Key Raw Materials Distribution
Table 101. Raw Materials Key Suppliers
Table 102. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 103. Milestones in Production Technology Evolution
Table 104. Distributors List
Table 105. Market Trends and Market Evolution
Table 106. Market Drivers and Opportunities
Table 107. Market Challenges, Risks, and Restraints
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
List of Figures
Figure 1. Sialylated Human Milk Oligosaccharides (HMO) Product Picture
Figure 2. Global Sialylated Human Milk Oligosaccharides (HMO) Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. 3'-Sialyllactose Product Picture
Figure 4. 6'-Sialyllactose Product Picture
Figure 5. Global Sialylated Human Milk Oligosaccharides (HMO) Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Infant Formula
Figure 7. Food
Figure 8. Others
Figure 9. Sialylated Human Milk Oligosaccharides (HMO) Report Years Considered
Figure 10. Global Sialylated Human Milk Oligosaccharides (HMO) Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2031) & (US$ Million)
Figure 12. Global Sialylated Human Milk Oligosaccharides (HMO) Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 13. Global Sialylated Human Milk Oligosaccharides (HMO) Revenue Market Share by Region (2020-2031)
Figure 14. Global Sialylated Human Milk Oligosaccharides (HMO) Sales (2020-2031) & (Tons)
Figure 15. Global Sialylated Human Milk Oligosaccharides (HMO) Sales (CAGR) by Region (2020-2031) (Tons)
Figure 16. Global Sialylated Human Milk Oligosaccharides (HMO) Sales Market Share by Region (2020-2031)
Figure 17. Top 5 and Top 10 Manufacturers Sialylated Human Milk Oligosaccharides (HMO) Sales Volume Market Share in 2024
Figure 18. Global Sialylated Human Milk Oligosaccharides (HMO) Revenue Market Share Ranking (2024)
Figure 19. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 20. 3'-Sialyllactose Revenue Market Share by Manufacturer in 2024
Figure 21. 6'-Sialyllactose Revenue Market Share by Manufacturer in 2024
Figure 22. Global Sialylated Human Milk Oligosaccharides (HMO) Sales Market Share by Type (2020-2031)
Figure 23. Global Sialylated Human Milk Oligosaccharides (HMO) Revenue Market Share by Type (2020-2031)
Figure 24. Global Sialylated Human Milk Oligosaccharides (HMO) Sales Market Share by Application (2020-2031)
Figure 25. Global Sialylated Human Milk Oligosaccharides (HMO) Revenue Market Share by Application (2020-2031)
Figure 26. North America Sialylated Human Milk Oligosaccharides (HMO) Sales YoY (2020-2031) & (Tons)
Figure 27. North America Sialylated Human Milk Oligosaccharides (HMO) Revenue YoY (2020-2031) & (US$ Million)
Figure 28. North America Top 5 Manufacturers Sialylated Human Milk Oligosaccharides (HMO) Sales Revenue (US$ Million) in 2024
Figure 29. North America Sialylated Human Milk Oligosaccharides (HMO) Sales Volume (Tons) by Type (2020- 2031)
Figure 30. North America Sialylated Human Milk Oligosaccharides (HMO) Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 31. North America Sialylated Human Milk Oligosaccharides (HMO) Sales Volume (Tons) by Application (2020-2031)
Figure 32. North America Sialylated Human Milk Oligosaccharides (HMO) Sales Revenue (US$ Million) by Application (2020-2031)
Figure 33. US Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2031) & (US$ Million)
Figure 34. Canada Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2031) & (US$ Million)
Figure 35. Mexico Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2031) & (US$ Million)
Figure 36. Europe Sialylated Human Milk Oligosaccharides (HMO) Sales YoY (2020-2031) & (Tons)
Figure 37. Europe Sialylated Human Milk Oligosaccharides (HMO) Revenue YoY (2020-2031) & (US$ Million)
Figure 38. Europe Top 5 Manufacturers Sialylated Human Milk Oligosaccharides (HMO) Sales Revenue (US$ Million) in 2024
Figure 39. Europe Sialylated Human Milk Oligosaccharides (HMO) Sales Volume (Tons) by Type (2020-2031)
Figure 40. Europe Sialylated Human Milk Oligosaccharides (HMO) Sales Revenue (US$ Million) by Type (2020-2031)
Figure 41. Europe Sialylated Human Milk Oligosaccharides (HMO) Sales Volume (Tons) by Application (2020-2031)
Figure 42. Europe Sialylated Human Milk Oligosaccharides (HMO) Sales Revenue (US$ Million) by Application (2020-2031)
Figure 43. Germany Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2031) & (US$ Million)
Figure 44. France Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2031) & (US$ Million)
Figure 45. U.K. Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2031) & (US$ Million)
Figure 46. Italy Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2031) & (US$ Million)
Figure 47. Russia Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2031) & (US$ Million)
Figure 48. Asia-Pacific Sialylated Human Milk Oligosaccharides (HMO) Sales YoY (2020-2031) & (Tons)
Figure 49. Asia-Pacific Sialylated Human Milk Oligosaccharides (HMO) Revenue YoY (2020-2031) & (US$ Million)
Figure 50. Asia-Pacific Top 8 Manufacturers Sialylated Human Milk Oligosaccharides (HMO) Sales Revenue (US$ Million) in 2024
Figure 51. Asia-Pacific Sialylated Human Milk Oligosaccharides (HMO) Sales Volume (Tons) by Type (2020- 2031)
Figure 52. Asia-Pacific Sialylated Human Milk Oligosaccharides (HMO) Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 53. Asia-Pacific Sialylated Human Milk Oligosaccharides (HMO) Sales Volume (Tons) by Application (2020-2031)
Figure 54. Asia-Pacific Sialylated Human Milk Oligosaccharides (HMO) Sales Revenue (US$ Million) by Application (2020-2031)
Figure 55. Indonesia Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2031) & (US$ Million)
Figure 56. Japan Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2031) & (US$ Million)
Figure 57. South Korea Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2031) & (US$ Million)
Figure 58. China Taiwan Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2031) & (US$ Million)
Figure 59. India Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2031) & (US$ Million)
Figure 60. Central and South America Sialylated Human Milk Oligosaccharides (HMO) Sales YoY (2020-2031) & (Tons)
Figure 61. Central and South America Sialylated Human Milk Oligosaccharides (HMO) Revenue YoY (2020-2031) & (US$ Million)
Figure 62. Central and South America Top 5 Manufacturers Sialylated Human Milk Oligosaccharides (HMO) Sales Revenue (US$ Million) in 2024
Figure 63. Central and South America Sialylated Human Milk Oligosaccharides (HMO) Sales Volume (Tons) by Type (2021-2031)
Figure 64. Central and South America Sialylated Human Milk Oligosaccharides (HMO) Sales Revenue (US$ Million) by Type (2020-2031)
Figure 65. Central and South America Sialylated Human Milk Oligosaccharides (HMO) Sales Volume (Tons) by Application (2020-2031)
Figure 66. Central and South America Sialylated Human Milk Oligosaccharides (HMO) Sales Revenue (US$ Million) by Application (2020-2031)
Figure 67. Brazil Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2025) & (US$ Million)
Figure 68. Argentina Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2025) & (US$ Million)
Figure 69. Middle East, and Africa Sialylated Human Milk Oligosaccharides (HMO) Sales YoY (2020-2031) & (Tons)
Figure 70. Middle East and Africa Sialylated Human Milk Oligosaccharides (HMO) Revenue YoY (2020-2031) & (US$ Million)
Figure 71. Middle East and Africa Top 5 Manufacturers Sialylated Human Milk Oligosaccharides (HMO) Sales Revenue (US$ Million) in 2024
Figure 72. Middle East and Africa Sialylated Human Milk Oligosaccharides (HMO) Sales Volume (Tons) by Type (2021-2031)
Figure 73. South America Sialylated Human Milk Oligosaccharides (HMO) Sales Revenue (US$ Million) by Type (2020-2031)
Figure 74. Middle East and Africa Sialylated Human Milk Oligosaccharides (HMO) Sales Volume (Tons) by Application (2020-2031)
Figure 75. Middle East and Africa Sialylated Human Milk Oligosaccharides (HMO) Sales Revenue (US$ Million) by Application (2020-2031)
Figure 76. GCC Countries Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2025) & (US$ Million)
Figure 77. Turkey Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2025) & (US$ Million)
Figure 78. Egypt Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2025) & (US$ Million)
Figure 79. South Africa Sialylated Human Milk Oligosaccharides (HMO) Revenue (2020-2025) & (US$ Million)
Figure 80. Sialylated Human Milk Oligosaccharides (HMO) Industry Chain Mapping
Figure 81. Regional Sialylated Human Milk Oligosaccharides (HMO) Manufacturing Base Distribution (%)
Figure 82. Global Sialylated Human Milk Oligosaccharides (HMO) Production Market Share by Region (2020-2031)
Figure 83. Sialylated Human Milk Oligosaccharides (HMO) Production Process
Figure 84. Regional Sialylated Human Milk Oligosaccharides (HMO) Production Cost Structure
Figure 85. Channels of Distribution (Direct Vs Distribution)
Figure 86. Bottom-up and Top-down Approaches for This Report
Figure 87. Data Triangulation
Figure 88. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Wireless Split Keyboard Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 18, 25
Global Ergonomic Adjustable Computer Chair Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 18, 25
Global Trackless Keyboard Tray Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 18, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232